Management of Hypertension according to JNC 7

Slides:



Advertisements
Similar presentations
CE REVIEW UNDERSTANDING HYPERTENSION. Hypertension is a chronic medical condition affecting more than 65 million Americans. Controlling hypertension is.
Advertisements

Preventing Strokes One at a Time Acute Interventions and Management 2009.
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
JNC 8 Guidelines….
ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
Hypertension – Summary
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Hypertension and The Older Patient
Hypertension in the Elderly
Drugs for Hypertension
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
Improving Hypertension Quality Measurement Using Electronic Health Records S Persell, AN Kho, JA Thompson, DW Baker Feinberg School of Medicine Northwestern.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
UPDATE ON MANAGEMENT OF HYPERTENSION. Classification of BLOOD PRESSURE for adults 18 yrs. Or older BP ClassificationSystolic BP, mm of hgDiastolic BP,
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
2007 Hypertension as a Public Health Risk January, 2007.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Internal Medicine Workshop Series Laos September /October 2009.
Pharmacy in Public Health: Describing Populations Course, date, etc. info.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Health Equity and Increasing Medication Adherence for High Blood Pressure Control Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH Professor of Medicine.
Hypertension In The Stroke Patient
David Antecol, M.D., FACC, FASH, FRCP(C) Specialist in Clinical Hypertension (American Society of Hypertension) Disclosures: None.
Hypertension guidelines What’s all the controversy about 2015
JNC VIII Hypertension.
Hypertension JNC VIII Guidelines.
Baseline characteristics and effectiveness results
Drugs for Hypertension
Health and Human Services National Heart, Lung, and Blood Institute
Vanguard Phase Results for the Blood Pressure Component
ALLHAT ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Copyright © 2007 American Medical Association. All rights reserved.
The Anglo Scandinavian Cardiac Outcomes Trial
Heart Health & Diabetes
Hypertension: A Risk Factor For Stroke
UNIT 2: ANTIHYPERTENSIVE DRUGS
Progress and Promise in RAAS Blockade
Step Care Therapy for Hypertension in Diabetic Patients
UNIT 2: ANTIHYPERTENSIVE DRUGS
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Primary Hypertension Max C. Reif, M.D.
The following slides highlight a report by Dr
Internal Medicine Workshop Series Laos September /October 2009
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Presentation transcript:

Management of Hypertension according to JNC 7 BY SANDAR KYI, MD

Introduction Hypertension is one of the most common worldwide diseases afflicting humans. Because of the associated morbidity and mortality and the cost to society, hypertension is an important public health challenge. In the US: Forty-three million people are estimated to have hypertension

Introduction Hypertension is the most important modifiable risk factor for coronary heart disease (the leading cause of death in North America), stroke (the third leading cause), congestive heart failure, end-stage renal disease, and peripheral vascular disease. Therefore, health care professionals must not only identify and treat patients with hypertension but also promote a healthy lifestyle and preventive strategies to decrease the prevalence of hypertension in the general population

Introduction Generally, the higher the blood pressure, the greater the risk. Untreated hypertension affects all organ systems and can shorten one's life expectancy by 10 to 20 years.

Introduction The question is, what are the barriers to the management of hypertension according to JNC 7?.

Hypothesis It is a hypothesis that barriers to the effective management of patient with uncontrolled hypertension include patient management time constraints, physician practice patterns, drug adverse effects, and patient specific factors such as lack of adherence to therapy, limited access to care, financial barriers related to the cost of medications & lack of knowledge about the seriousness of uncontrolled hypertension.

Methods Random chart reviews of 200 patients out of 500 charts those are following in FCC of RCRMC for hypertension from 2000-2006. Sex – F:M 157:43 Race – Hispanic : Non-Hispanic 115 : 85 Smoker : Non Smoker - 58:142 Inclusion Criteria : pt with pre-hypertension, HTN stage 1,stage 2 according to JNC 7.

Methods All charts were reviewed following factors: - Demographic factor: age, sex, culture background, first language -co-morbidity: hypercholesterolemia, IHD, diabetes outcome of BP treatment: acute coronary event (CP, angina, MI,CHF, bypass surgery) stroke (TIA, CVA both ischemic and hemorrhagic) BP whether reached goal BP or not

JNC VII report recommendations Initial therapy based on the JNC VII report recommendations is as follows: Prehypertension (systolic 120-139, diastolic 80-89): No antihypertensive drug is indicated. (f/up BP measure within 1 yr). Stage 1 hypertension (systolic 140-159, diastolic 90-99): Thiazide-type diuretics are recommended for most. ACE inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, calcium channel blocker, or combination may be considered. Stage 2 hypertension (systolic more than 160, diastolic more than 100): Two-drug combination (usually thiazide-type diuretic and ACE inhibitor or ARB or beta-blocker or calcium channel blocker) is recommended for most. For the compelling indications, other antihypertensive drugs (eg, diuretics, ACE inhibitor, ARB, beta-blocker, calcium channel blocker) may be considered as needed.

JNC 7 Reference Card

JNC 7 Reference Card

Number of patients with HTN who f/up in FCC

Number of patients with HTN who did not reach goal BP

Complication in non-compliant patients

Complication in patient whose Dr not following JNC 7

Complication in patients who did not take med: due to SE

Complication in patients who reached goal BP

% of Acute Coronary Event Complication

Numbers of patients with co-morbidity In pts who reached goal BP - 18 (25%) In pts who were non-compliant – 34 (52%) In pts who didn’t take med: due to SE – 10 (32%) In pts whose Dr not following JNC 7- 15 (47%)

Numbers of patients with co-morbidity

Discussion Thus, according to this study, patient non-compliant had been identified as one of the main reasons that BP therapy fails. Drug adverse effects have also been identified as a factor related to physician prescribing pattern of hypertensive medications.

Discussion Other findings seem to suggest that physicians are familiar with the JNC 7 guidelines for treating HTN but do not implement this knowledge into their everyday practice. BP is one of the contributing factor to get complication but other co-morbidities (high cholesterol, DM ) can also contribute to complications.

Conclusion This study clearly demonstrates that positive association between uncontrolled HTN & complication (such as cardiovascular disease , CVA,). The finding of this study provide useful information for designing effective physician interventions for the management of patients with uncontrolled HTN.

Limitations of Research Study Small sample sizes with 6yrs duration. Didn’t review patient cultural background, educational status, BMI, smoking history details, control of diabetic, & control of hypercholesterolemia. Also not mentioned Duration of Physician time spent with pt. Usage of language interpreter if pt doesn’t speak English as first language.

Recommendation Further extensive study to include following factors: patient cultural background, educational status, BMI, smoking history details, control of diabetic & control of hypercholesterolemia. Duration of Physician time spent with pt. Usage of language interpreter if pt doesn’t speak English as first language.

References Barriers to Blood Pressure Control G. Divakara Murthy Archives of Internal Medicine E-medicine HTNSat Sharma, MD, FRCPC, FACP, FCCP, DABSM, Program Director, Associate Professor, Department of Internal Medicine, Divisions of Pulmonary and Critical Care Medicine, University of Manitoba; Site Director of Respiratory Medicine, St Boniface General Hospital The National High Blood Pressure Education Program

Thank you!